全文获取类型
收费全文 | 96315篇 |
免费 | 11052篇 |
国内免费 | 6407篇 |
专业分类
耳鼻咽喉 | 788篇 |
儿科学 | 1671篇 |
妇产科学 | 973篇 |
基础医学 | 8393篇 |
口腔科学 | 1883篇 |
临床医学 | 13705篇 |
内科学 | 10728篇 |
皮肤病学 | 988篇 |
神经病学 | 3177篇 |
特种医学 | 3477篇 |
外国民族医学 | 36篇 |
外科学 | 6369篇 |
综合类 | 22364篇 |
现状与发展 | 34篇 |
一般理论 | 1篇 |
预防医学 | 9521篇 |
眼科学 | 2712篇 |
药学 | 12003篇 |
183篇 | |
中国医学 | 8666篇 |
肿瘤学 | 6102篇 |
出版年
2024年 | 347篇 |
2023年 | 1598篇 |
2022年 | 3478篇 |
2021年 | 5328篇 |
2020年 | 4544篇 |
2019年 | 3156篇 |
2018年 | 3190篇 |
2017年 | 3754篇 |
2016年 | 2994篇 |
2015年 | 4960篇 |
2014年 | 6137篇 |
2013年 | 6610篇 |
2012年 | 9255篇 |
2011年 | 9842篇 |
2010年 | 7235篇 |
2009年 | 5913篇 |
2008年 | 6405篇 |
2007年 | 5961篇 |
2006年 | 5450篇 |
2005年 | 4240篇 |
2004年 | 2854篇 |
2003年 | 2620篇 |
2002年 | 1975篇 |
2001年 | 1569篇 |
2000年 | 1193篇 |
1999年 | 836篇 |
1998年 | 438篇 |
1997年 | 419篇 |
1996年 | 302篇 |
1995年 | 308篇 |
1994年 | 222篇 |
1993年 | 110篇 |
1992年 | 90篇 |
1991年 | 77篇 |
1990年 | 78篇 |
1989年 | 58篇 |
1988年 | 60篇 |
1987年 | 33篇 |
1986年 | 26篇 |
1985年 | 16篇 |
1984年 | 10篇 |
1983年 | 5篇 |
1982年 | 8篇 |
1981年 | 11篇 |
1980年 | 9篇 |
1979年 | 12篇 |
1978年 | 4篇 |
1977年 | 6篇 |
1970年 | 7篇 |
1966年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
Jing Yang Changqing Liu Linxia Zhang Yanhui Liu Aihua Guo Huiwu Shi Xiaoxia Liu Ying Cheng 《Inflammation》2015,38(4):1415-1423
63.
Shiyu Jiang Yan Qin Hongxin Jiang Biao Liu Jianming Shi Fanlu Meng Peng Liu Jianliang Yang Sheng Yang Xiaohui He Shengyu Zhou Lin Gui Hao Liu Jing Lin Han Han-Zhang Yuankai Shi 《International journal of cancer. Journal international du cancer》2020,147(9):2611-2620
Diffuse large B-cell lymphoma (DLBCL) is a clinically aggressive and heterogenous disease. Although most patients can be cured by immunochemotherapy, 30% to 40% patient will ultimately develop relapsed or refractory disease. Here, we investigated the molecular landscapes of patients with diverse responses to R-CHOP. We performed capture-based targeted sequencing on baseline samples of 105 DLBCL patients using a panel consisting of 112 lymphoma-related genes. Subsequently, 81 treatment-naïve patients with measurable disease and followed for over 1 year were included for survival analysis. Collectively, the most commonly seen mutations included IGH fusion (69%), PIM1(33%), MYD88 (29%), BCL2 (29%), TP53 (29%), CD79B (25%) and KMT2D (24%). Patients with TP53 mutations were more likely to have primary refractory disease (87.0% vs 50.0%, P = .009). For those with TP53 disruptive mutations, 91.7% patients were in the primary refractory group. Interestingly, BCL-2 somatic hypermutation was only seen in patients without primary refractory disease (P = .014). In multivariate analysis, BCL-2 amplification (hazard ratio [HR] = 2.94, P = .022), B2M mutation (HR = 2.99, P = .017) and TP53 mutation (HR = 3.19, P < .001) were independently associated with shorter time to progression (TTP). Furthermore, TP53 mutations was correlated with worse overall survival (P = .049). Next, we investigated mutation landscape in patients with wild-type (WT) TP53 (n = 58) and found that patients harboring MYD88 L265P had significantly inferior TTP than those with WT or non-265P (P = .046). Our study reveals the mutation spectrum of treatment-naive Chinese DLBCL patients. It also confirms the clinical significance of TP53 mutations and indicates the prognostic value of MYD88 L265P in TP53 WT patients. 相似文献
64.
Xiaoxv Dong Yawen Zeng Yi Liu Longtai You Xingbin Yin Jing Fu Jian Ni 《Phytotherapy research : PTR》2020,34(2):270-281
Aloe‐emodin is a naturally anthraquinone derivative and an active ingredient of Chinese herbs, such as Cassia occidentalis, Rheum palmatum L., Aloe vera, and Polygonum multiflorum Thunb. Emerging evidence suggests that aloe‐emodin exhibits many pharmacological effects, including anticancer, antivirus, anti‐inflammatory, antibacterial, antiparasitic, neuroprotective, and hepatoprotective activities. These pharmacological properties lay the foundation for the treatment of various diseases, including influenza virus, inflammation, sepsis, Alzheimer's disease, glaucoma, malaria, liver fibrosis, psoriasis, Type 2 diabetes, growth disorders, and several types of cancers. However, an increasing number of published studies have reported adverse effects of aloe‐emodin. The primary toxicity among these reports is hepatotoxicity and nephrotoxicity, which are of wide concern worldwide. Pharmacokinetic studies have demonstrated that aloe‐emodin has a poor intestinal absorption, short elimination half‐life, and low bioavailability. This review aims to provide a comprehensive summary of the pharmacology, toxicity, and pharmacokinetics of aloe‐emodin reported to date with an emphasis on its biological properties and mechanisms of action. 相似文献
65.
66.
Sequential Therapy Based on Evolvement of Patterns: A New Model for Treatment of Alzheimer’s Disease
In order to solve the problem of long-term (>9 months) efficacy in the treatment of Alzheimer''s disease (AD) by conventional therapy (CT), a staged and multiply-targeted sequential therapy based on the evolvement of patterns (STEP) was developed. Its main innovations include: (1) the time order of evolution of patterns defined by Chinese medicine (CM) in AD was found, that is, "the orderly pattern evolution starting from Shen (Kidney) deficiency, progressing to phlegm, stasis and fire, and worsening to severe toxin as well as functional collapse"; (2) the cascade hypothesis of Shen deficiency in AD and its sequential therapy based on Shen-reinforcing was proposed, that is, "reinforcing Shen in the early stage and throughout the whole process, resolving phlegm, activating blood and purging fire in the middle stage, detoxifying and replenishing vitality to stop the collapse in the advanced stage", and through meta-analysis, clinical drug use was optimized, thus the leap from "inferential selection" to "evidence-based selection" was realized; (3) the STEP regimen combined with CT maintained cognitive and behavioral stability in AD patients for at least 12 months, with cognitive enhancement and behavioral synergy after 9 months, and cognitive benefit was superior to CT at 9, 12, 15, 18, 21, and 24 months, respectively. The 2-year cognitive improvement rate was increased by 25.64% (P=0.020) and the cognitive deterioration rate was decreased by 48.71% (P=0.000). Among them, the cognitive and functional benefits of Shen-reinforcing therapy for very early AD (350 cases) for 1 year were better than the placebo (P<0.001), and the dementia conversion rate was reduced by 8.85% (P=0.002). The behavioral symptomatic relief of patients with vascular dementia received fire-purging therapy (540 cases) was superior to those received CT (P=0.016). These data suggested that the STEP regimen has synergistic effects on CTs at least in terms of cognitive benefit, and the earlier the use, the greater the benefit will have. Therefore, the STEP regimen should be considered as one of the clinical options, particularly for the dearth of effective pharmaceutical or immunological interventions that are currently available for AD. 相似文献
67.
68.
目的:探讨肾炎1号方联合西药治疗肾病综合征临床疗效及对患者凝血指标、免疫功能的影响。方法:选取肾病综合征患者共52例,分为对照组26例、治疗组26例。两组患者均予以基础治疗,对照组在基础治疗上给予泼尼松片治疗。治疗组在对照组基础上加用肾炎1号方治疗。结果:与对照组治疗后相比,治疗组治疗24 h后Upr、CHOL、TG、Scr、Fg、D-D均下降,差异有统计学意义(P<0.05)。治疗组治疗后补体C3升高明显,与对照组比较,差异有统计学意义(P<0.05)。治疗后治疗组中医证候积分各项均低于对照组,治疗组总有效率88.46%高于对照组的76.92%,差异均有统计学意义(P<0.05)。结论:肾炎1号方联合西药治疗肾病综合征临床效果较好,能更有效地控制患者蛋白尿、升高血清白蛋白水平、降低血清胆固醇,并且能调节机体体液免疫紊乱、改善高凝状态。 相似文献
69.
70.